Two Republican senators are calling for the reauthorization of the FDA user fee act as a catalyst for changes at the agency. In a letter addressed to the various councils representing the life sciences industry, Sens. Richard Burr (R-NC) and Tom Coburn (R-OK) wrote that “reauthorization of the U.S. Food and Drug Administration user fee agreements provides an important opportunity to address the root causes of the threats to our nation’s leadership in medical innovation.” “As you negotiate the next user fee agreement and prepare to submit the proposal to congress, we wish to underscore the necessity of restoring regulatory certainty and predicability,” they wrote.
